However, the T cells not only kill cancer cells – they additionally destroy the tumor blood vessel system, thus impeding the supply of nutrients to the tumor. Consequently, “escapee” mutant tumor cells are eradicated that have become resistant to drug-based treatment and are responsible for tumor recurrence. (Cancer Cell, doi10.1016/j.ccr.2011.10.019)*.
The researchers transplanted tumor cells into mice that express SV40 large T antigen (Tag), the oncogene that is critical for tumor growth. The researchers were thus able to target and inactivate the oncogene using the antibiotic drug doxycycline (dox), which has an effect similar to modern drugs currently in clinical use. Since the oncogene is also present as antigen on the surface of the tumor cells, the researchers were also able to target these tumors with oncogene-specific T cells. Thus, for the first time the effect of the two completely different therapy approaches could be compared directly with each other.
Moreover, a special feature of the study was that the tumors in the mice were large – bigger than one centimeter and containing about one billion cancer cells, comparable to clinical-size tumors in patients. Only then, according to the researchers, is the development of the tumor tissue (tumor stroma), which also includes the tumor vasculature, complete. The tumor is then considered “established”. The aim of tumor therapy is to kill all cancer cells to prevent the recurrence of cancer disease.
The researchers showed in mice that the tumor is destroyed by the drug-mediated inactivation of the oncogene, but that the tumor vasculature and thus the blood supply of the tumor remains intact. In addition, due to a high mutation rate, some cancer cells become resistant to the drug and quickly generate new tumors despite continual administration of the anti-cancer drug.
Adoptive T-cell therapy, the researchers noted, is more effective in the mice in the long term, because it destroys the blood supply of the tumor. In addition, it evidently intercepts cancer cells that have altered their characteristics via mutations and thus escape drug treatment. In adoptive T-cell therapy, the researchers modulate the cytotoxic T cells (immune cells toxic for the cell) in the test tube in such a way that the T cells recognize certain features on the surface of cancer cells and specifically destroy the tumor cells. Then these primed immune cells are transferred back into the mice. The researchers point out that techniques to produce highly specialized T cells against human tumors have recently been developed following previous studies by Professor Blankenstein’s research group. Now it will be important to determine exactly how these immune cells can be used in future clinical trials.
The researchers hope that their insights in defining optimal conditions for T cell therapy may help improve future clinical trials and thus the treatment of cancer patients.
*Oncogene-targeting T cells reject large tumors, while oncogene inactivation selects escape variants in mouse models of cancer
Kathleen Anders1, Christian Buschow2, Andreas Herrmann3, Ana Milojkovic4, Christoph Loddenkemper5, Thomas Kammertoens2, Peter Daniel4, Hua Yu3, Jehad Charo1, Thomas Blankenstein1,2,*1Max Delbrück Center for Molecular Medicine, 13092 Berlin, Germany
5Institute of Pathology, Charité Campus Benjamin Franklin, 12200, Berlin, GermanyContact:
Barbara Bachtler | Max-Delbrück-Centrum
Research team of the HAW Hamburg reanimated ancestral microbe from the depth of the earth
01.03.2017 | Hochschule für Angewandte Wissenschaften Hamburg
Researchers Imitate Molecular Crowding in Cells
01.03.2017 | Universität Basel
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
01.03.2017 | Health and Medicine
01.03.2017 | Physics and Astronomy
01.03.2017 | Life Sciences